Lv51
1460 积分 2024-08-01 加入
VP3-2024: A randomized study of 6 vs 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse
1个月前
已完结
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
Sunitinib in metastatic renal cell carcinoma patients with brain metastases
1个月前
已完结
Outcome of Patients With Renal Cell Carcinoma Metastatic to the Brain Treated With Sunitinib Without Local Therapy
1个月前
已完结
Safety and Efficacy of Sunitinib in Patients from Italy with Metastatic Renal Cell Carcinoma: Final Results from an Expanded-Access Trial
1个月前
已完结
Sunitinib malate in solitary fibrous tumor (SFT)
4个月前
已完结
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
4个月前
已完结
Neoadjuvant therapy in renal cell carcinoma with tumor thrombus: A systematic review and meta-analysis
5个月前
已完结
Sorafenib and radioiodine-refractory differentiated thyroid cancer (RR-DTC): a systematic review and meta-analysis
8个月前
已完结
Sorafenib: a review of its use in patients with radioactive iodine-refractory, metastatic differentiated thyroid carcinoma
8个月前
已完结
皖公网安备34019202002308
